Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 687 across all filing types
Latest filing 2022-10-17 Regulatory Filings
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Pause in trading 1 page 110.8KB
Regulatory Filings Classification · 95% confidence The document is a short market release announcing a temporary pause in trading of the company's securities. It is dated and signed by ASX Listings Compliance. There is no financial data, report content, or detailed analysis. The document is an official regulatory announcement related to trading status, not a financial report or detailed filing. Given its brevity and nature, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2022-10-17 English
R327 COVID Study Update 4 pages 402.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement providing an update on a specific study related to the company's product RECCE 327 and its efficacy against SARS-CoV-2 in animal models. It includes study highlights, patent lodgement information, and strategic focus updates. There are no financial statements, detailed financial analysis, or comprehensive report data. The document is a corporate announcement about research progress and patent filings rather than a formal financial or regulatory report. It fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement and does not match other specific categories like Annual Report, Earnings Release, or Investor Presentation.
2022-10-17 English
Notice of Annual General Meeting/Proxy Form 37 pages 6.8MB
AGM Information Classification · 100% confidence The document is an ASX announcement titled 'Notice of 2022 Annual General Meeting' and includes the Notice of Meeting, Proxy Form, Fact Sheet, and related documents. It details the date, time, and location of the AGM, voting instructions, proxy submission methods, and shareholder communication preferences. The content is focused on informing shareholders about the upcoming AGM and how to participate, rather than presenting financial results or management discussion. The document is lengthy (15,000 characters) and contains the full Notice and explanatory statements, not just a brief announcement or link. Therefore, it is classified as AGM Information (AGM-R).
2022-10-13 English
Expansion and Acceleration of Clinical Programs 4 pages 312.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Recce Pharmaceuticals detailing updates on clinical programs, including Phase I and Phase II clinical trials, pre-clinical program progress, and future plans. It focuses on clinical development progress and timelines rather than presenting financial data or comprehensive company performance. There is no indication of financial statements, audit information, or regulatory certifications. The document is a corporate announcement about clinical program expansion and acceleration, which fits best under a general regulatory announcement category. It is not a full financial report, earnings release, or investor presentation. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-09-26 English
2022 Annual General Meeting 2 pages 234.9KB
AGM Information Classification · 100% confidence The document is an ASX announcement notifying the date of the company's upcoming Annual General Meeting (AGM). It provides the date and time of the AGM and mentions that further details will be provided in the notice of meeting. There is no financial data, no detailed report, no voting results, and no other substantive content beyond the AGM date notification. The document length is short (2654 characters), and it is clearly an announcement about the AGM date rather than the AGM materials themselves. Therefore, the document fits the category of AGM Information (AGM-R).
2022-09-20 English
Application for quotation of securities - RCE 6 pages 27.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX by Recce Pharmaceuticals Ltd. It details the issuance and conversion of options into ordinary fully paid shares, the number of securities to be quoted, issue dates, and other issuance details. There is no financial performance data, management discussion, or regulatory certification. The document is an announcement related to capital changes, specifically the issuance and quotation of new shares resulting from option exercises. This fits the definition of a Share Issue/Capital Change announcement (SHA). The document length and content confirm it is not a brief report publication announcement or a regulatory filing. Therefore, the classification is SHA with high confidence.
2022-09-14 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.